Physician profile
Thomas K Slabaugh
NPI 1831293232
$825.30
in general payments reported to CMS, 2019-2025
17 companies · $94.71 in 2025
The $94.71 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $87.50 · 2020: $167 · 2021: $158 · 2022: $121 · 2023: $96.91 · 2024: $101 · 2025: $94.71.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $292.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $292.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $158.40 | 2022-2024 | |
| Boston Scientific Corporation | $157.81 | 2021 | |
| Urogen Pharma, INC. | $93.24 | 2022-2025 | |
| Integra Lifesciences Corporation | $88.00 | 2020 | |
| Procept Biorobotics Corporation | $50.16 | 2019-2024 | Aquabeam System |
| Myovant Sciences INC. | $44.56 | 2022 | |
| Accord Healthcare, INC. | $42.71 | 2025 | |
| Dentsply Ih INC. | $27.47 | 2019-2020 | |
| Mission Pharmacal Company | $23.80 | 2019-2020 | |
| Axonics, INC. | $23.14 | 2023 | Bulkamid, Axonics |
| Janssen Biotech, INC. | $21.73 | 2025 | Erleada |
| Astellas Pharma US INC | $21.35 | 2020 | |
| Neotract INC. | $15.96 | 2019 | |
| Antares Pharma, INC. | $15.90 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.48 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $12.94 | 2020 | |
| Ferring Pharmaceuticals INC. | $12.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Slabaugh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.